Eloxx Pharmaceuticals, INC

Eloxx Pharmaceuticals reported strong Q2 2026 results, highlighted by a $66 million public offering, Nasdaq uplisting, and progress in clinical trials for exaluren in rare kidney diseases.

Eloxx Pharmaceuticals has appointed two new directors and implemented a 1-for-11 reverse stock split, reducing authorized shares.

Eloxx Pharmaceuticals stockholders approved a reverse stock split and an increase in equity incentive plan shares.

Eloxx Pharmaceuticals announces the resignation of director Ms. Lindsay Androski, effective August 6, 2025, citing no disagreements with company operations.

Eloxx Pharmaceuticals' Board of Directors approved a stock option repricing for the CEO, reducing the exercise price to $0.0001 per share and accelerating the vesting of existing options.

Eloxx Pharmaceuticals has amended its loan agreement with Hercules Capital and entered into a royalty agreement with SD MF, securing additional funding and establishing revenue-sharing terms.

Eloxx Pharmaceuticals, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased operating expenses, significant net losses, and a substantial accumulated deficit, while also highlighting a recent public offering and Nasdaq uplisting.

Domicilium Real Estate Fund III LP reported the conversion of pre-funded warrants into 600,000 shares of Eloxx Pharmaceuticals common stock.

Director Stephen W. Webster was granted 13,587 stock options in Eloxx Pharmaceuticals as part of standard equity compensation.

Director Alan Edmund Walts was granted 8,590 stock options in Eloxx Pharmaceuticals as part of a compensation arrangement.

Director Nina S. Kjellson was granted 13,587 stock options in Eloxx Pharmaceuticals, Inc. as part of a standard equity compensation plan.

Eloxx Pharmaceuticals CEO Sumit Aggarwal has been granted 328,833 stock options following the satisfaction of performance-based vesting conditions.

Director Steven D. Rubin was granted 4,018 stock options in Eloxx Pharmaceuticals, Inc. as part of a compensation arrangement.

Eloxx Pharmaceuticals files Amendment No. 2 to its S-1 registration statement for a $66 million common stock and pre-funded warrant offering.

Eloxx Pharmaceuticals, Inc. has filed an S-1/A amendment to its registration statement, detailing plans to offer shares of common stock and pre-funded warrants, aiming for a Nasdaq Capital Market listing.

Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company, is seeking to raise capital and uplist its common stock to the Nasdaq Capital Market to fund the advancement of its lead product candidate, exaluren, for rare kidney diseases.

Samsara BioCapital entities and Srinivas Akkaraju have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of Eloxx Pharmaceuticals' common stock.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has disclosed beneficial ownership of 400,000 shares, representing 9.91% of Eloxx Pharmaceuticals' common stock as of June 30, 2026.

Aberdeen Group plc and abrdn Inc. have jointly reported beneficial ownership of 9.91% of Eloxx Pharmaceuticals Inc. common stock as of June 30, 2026.

Coastlands Capital LP and affiliates have reported a 9.99% beneficial ownership stake in Eloxx Pharmaceuticals, Inc. through common stock and pre-funded warrants.

Domicilium Capital Partners and associated entities have filed a Schedule 13G reporting a 19.99% beneficial ownership stake in Eloxx Pharmaceuticals, Inc.

EcoR1 Capital, LLC and Oleg Nodelman have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Eloxx Pharmaceuticals, Inc.